{"title":"Use of real-world data for drug development","authors":"A.S. Kolbin, R.R. Niyazov, V.V. Kalinichenko, S.V. Glagolev","doi":"10.32756/0869-5490-2023-4-16-23","DOIUrl":null,"url":null,"abstract":"The use of real-world data (RWD) and real-world evidence (RWE) is an international trend in the modern healthcare system. In a review article, the authors highlight the use of RWD/RWE for drug development in the following categories: drug-drug interactions; dose selection in special populations such as patients with elimination organ dysfunction; dosing optimization in children; the use of quantitative clinical pharmacology in model-based drug development; use of RWE as a parallel data source to complement a randomized controlled trial to extend indications; RWD/RWE to create an external control group for rare diseases.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2023-4-16-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The use of real-world data (RWD) and real-world evidence (RWE) is an international trend in the modern healthcare system. In a review article, the authors highlight the use of RWD/RWE for drug development in the following categories: drug-drug interactions; dose selection in special populations such as patients with elimination organ dysfunction; dosing optimization in children; the use of quantitative clinical pharmacology in model-based drug development; use of RWE as a parallel data source to complement a randomized controlled trial to extend indications; RWD/RWE to create an external control group for rare diseases.